Biotech and Life Sciences
Simmunome secures pre-seed financing
Armstrong Murira and Nardin Nakhla founded Simmunome secured $2M seed funding from Theodorus Investment Funds, BKR Capital, Sandpiper Ventures, Fonds d’investissement Eurêka, and ACET Capital. Theodorus' Theo Risopoulos, BKR's Lise Birikundavyi and Sandpiper's Rhiannon Davis joined Simmunome board.
DalCor Pharmaceuticals secures US $80M Series D
DalCor Pharmaceuticals Canada raised US $80M Series D funding from Investissement Québec, Fonds Propres d’Investissement Québec, Andes Growth, TB Pharma, Fonds de Solidarité FTQ, and CTI Life Sciences.
Cerba HealthCare to acquire Canadian Contract Research Laboratory CIRION
EQT Private Equity and PSP Investments backed Cerba HealthCare acquired CIRION BioPharma Research Inc. from founders Dr. Sylvain Desrochers and Dr. Lise Dallaire
Novo Nordisk to acquire Inversago Pharma for up to US $1.1B
Novo Nordisk A/S to acquire Inversago Pharma for up to US $1.075B from Forbion, New Enterprise Associates (NEA), adMare BioInnovations, Anges Québec Capital (AQC), Amgen Ventures, AmorChem, Fonds de solidarité FTQ, Genesys Ventures, JDRF T1D Fund, Tarnagulla Ventures Fund, and others.
Liberum Biotech secures seed financing
Ryan Fobel, Keith Pardee, Aidan Tinafar founded Liberum Biotech secured US $1.8M seed funding led by TechU Ventures with participation of SOSV and Savantus Ventures.
3D BioFibR secures $3.52M seed financing
3D BioFibR secured $3.52M in seed funding led by Invest Nova Scotia with matching investment from Build Ventures and from returning investors Concrete Ventures and Globalive Capital.
Neptune Nanotechnologies secures $1.8M seed financing
Aaron Guan founded Neptune Nanotechnologies secured $1.8M seed funding led by China Canada Angel Alliance (CCAA) with participation of Ontario Centre of Innovation (OCI), Liquid Metal VC, and private investors.
Bausch Health secures US $600M financing facility With KKR
Bausch Health Companies thorough Bausch Receivables Funding LP, an Ontario limited partnership and a wholly-owned subsidiary, entered into a US $600M non-recourse financing facility with KKR and its credit funds and accounts.
NeuroServo secures $2.2M seed financing
Nicolas Tremblay and Jérôme Arnaud founded NeuroServo secured $2.2M seed funding from Desjardins Capital, Investissement Québec, CABHI (Centre for Aging + Brain Health Innovation), and private investors.
Feldan Therapeutics announces initial close of $16.5M Series B
Feldan Therapeutics secured $16.5M Series B funding from Investissement Québec, Amgen Ventures, GC Cell, FSIT2, GC Holdings, other existing shareholders.
AtomVie secures $50M additional Series A funding
CPDC (Centre for Probe Development and Commercialization) spinout AtomVie Global Radiopharma Inc. secured $50M tranche 2 Series A financing led by Avego Management, LLC.
MPM BioImpact to take Reunion Neuroscience private for US $13M
MPM BioImpact entered into agreement to acquire Reunion Neuroscience Inc. (NASDAQ/TSX: REUN) at US $1.12 per share in an all-cash transaction for approximately US $13.1 million.
BenchSci secures US $70M Series D
Thomas Leung, Liran Belenzon and Elvis Wianda founded BenchSci secured US $70M Series D funding led by Generation Investment Management, with participation from existing investors iNovia Capital, TCV, Golden Ventures and F-Prime Capital
Swiftsure Innovations secures $2.3M seed financing
Deanne McCarthy founded Swiftsure Innovations secured $2.3M seed funding led by Pelorus VC with participation from Sandpiper Ventures, MEDTEQ+ and several other pre-seed investors.
Ethnocare secures $2.5M seed funding led by AQC Capital and Anges Québec
Marc-Antoine Malouin, Louis-Philippe Garneau, and Vincent Breton founded Ethnocare secured $2.5M seed funding led by AQC Capital and Anges Québec, including $670K in financial support from Government of Quebec’s Impulsion PME program/Investissement Québec
Recursion to acquire Cyclica and Valence in all stock transactions
Recursion to acquire Cyclica for US $40M from Naheed Kurji, Drive Capital, Chiesi Farmaceutici, GreenSky Capital, others, and Valence for US $47.5M from Daniel Cohen and Therence Bois, Fifty Years, Air Street Capital, Amplitude Ventures, Phoenix Venture Partners, others
uBriGene Biosciences secures ¥150M Series C+ funding
uBriGene Biosciences, Chinese company with offices in Vancouver and Rockville, MD, raised ¥150M （人民幣）or US $20M in Series C+ funding.
ODAIA Intelligence secures US $25M Series B
ODAIA secured US $25M Series B led by Threshold Ventures and Monograph Capital with participation of Wittington Ventures, Flint Capital, BDC Capital, StandUp Ventures and Graphite Ventures. Emily Melton from Threshold Ventures and Charles Conn from Monograph Ventures will join ODAIA's board.
